Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China · Delayed Price · Currency is CNY

8.59

+0.14 (1.66%)

Sep 2, 2026, 3:00 PM CST

Cabio Biotech (Wuhan) Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	313.99	563.14	555.59	443.8	433.42	351.11
Revenue Growth	-47.80%	1.36%	25.19%	2.40%	23.44%	8.55%
Gross Profit	86.45	250.37	223.72	179.29	176.29	178.78
Operating Income	-41.81	129.54	97.9	76.08	64.35	101.7
Net Income	-64.8	143.72	124.21	91.37	64.37	128.58
Earnings Per Share	-0.39	0.86	0.74	0.54	0.38	0.76
EPS Growth	-	16.22%	37.04%	42.10%	-50.28%	-1.84%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
ARA	387.61
DHA	123.6
Total	511.21

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	351.48	278.23	153.18	239.71	527.13	675.97
Total Debt	176.07	86.28	19.29	12.76	33.05	2.42
Net Cash (Debt)	175.42	191.95	133.89	226.95	494.08	673.55
Net Cash Growth	-14.39%	43.37%	-41.01%	-54.07%	-26.65%	-21.76%
Net Cash Per Share	1.05	1.15	0.80	1.34	2.92	4.00

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	143.85	270.07	173.04	68.89	176.4	103.29
Capital Expenditures	-107.5	-144.54	-211.6	-297.68	-249.47	-173.43
Free Cash Flow	36.36	125.53	-38.55	-228.79	-73.07	-70.14
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	27.53%	44.46%	40.27%	40.40%	40.67%	50.92%
Operating Margin	-13.31%	23.00%	17.62%	17.14%	14.85%	28.97%
Pretax Margin	-21.35%	28.82%	25.17%	22.53%	18.03%	43.31%
Profit Margin	-20.64%	25.52%	22.36%	20.59%	14.85%	36.62%
FCF Margin	11.58%	22.29%	-6.94%	-51.55%	-16.86%	-19.98%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.201	-	0.201	0.200	0.214	0.236
Dividend Per Share Growth	0.47%	-	0.47%	-6.67%	-9.08%	0%
Dividend Yield	2.33%	-	1.06%	1.14%	0.69%	0.56%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	27.02	25.79	32.97	84.48	57.34
Forward PE	-	19.04	22.89	23.21	32.26	38.73
P/FCF Ratio	38.23	30.93	-	-	-	-
PS Ratio	4.43	6.90	5.77	6.79	12.55	21.00